tradingkey.logo

Simulations Plus Q1 revenue beats expectations

ReutersJan 8, 2026 9:14 PM


Overview

  • Drug development firm's fiscal Q1 revenue decreased 3%, beating analyst expectations

  • Adjusted EPS for fiscal Q1 met analyst expectations

  • Company reaffirmed fiscal 2026 guidance and plans Investor Day for new product vision


Outlook

  • Simulations Plus reaffirms fiscal 2026 revenue guidance of $79 mln to $82 mln

  • Company expects fiscal 2026 adjusted diluted EPS of $1.03 to $1.10

  • Simulations Plus anticipates fiscal 2026 adjusted EBITDA margin of 26% to 30%


Result Drivers

  • SERVICES GROWTH - Significant growth in commercialization offerings and modest gains in development projects drove services revenue increase

  • SOFTWARE DECLINE - Expected decrease in clinical operations and development revenue contributed to software revenue decline

  • MARKET DYNAMICS - Favorable market dynamics and strong bookings in software and services support confidence in fiscal year guidance


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Revenue

Beat

$18.40 mln

$18.10 mln (6 Analysts)

Q1 Adjusted EPS

Meet

$0.13

$0.13 (2 Analysts)

Q1 Net Income

$700,000

Q1 Adjusted EBITDA

$3.50 mln

Q1 Gross Margin

59.00%


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Simulations Plus Inc is $22.50, about 18.5% above its January 7 closing price of $18.99

  • The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 37 three months ago

Press Release: ID:nBw5GNmYMa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI